• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

58.22 +0.72 (+1.25%)
Streaming Delayed Price Updated: 10:17 AM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oruka Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
May 13, 2026
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
May 13, 2026
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
May 13, 2026
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications. 
Via The Motley Fool
Topics Regulatory Compliance
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗
September 29, 2025
Via Stocktwits
News headline image
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? ↗
May 11, 2026
It's not the news that AbbVie needed, given the challenging year it is having. 
Via The Motley Fool
News headline image
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
April 28, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
These stocks are gapping in today's session ↗
April 27, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 27, 2026
Via Chartmill
News headline image
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
April 26, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗
April 21, 2026
This Menlo Park biotech, focused on monoclonal antibody therapies, reported a notable insider sale amid a year of dramatic share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
March 18, 2026
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
March 18, 2026
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
March 15, 2026
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
Let's take a look at the stocks that are in motion in today's session. ↗
March 13, 2026
Via Chartmill
News headline image
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 12, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
February 09, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
January 12, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces New Board Member and Board Transition
December 11, 2025
Appoints accomplished commercial leader Chris Martin to its Board of Directors 
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
November 13, 2025
 
Via Benzinga
News headline image
AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗
November 13, 2025
 
Via Benzinga
News headline image
Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗
November 12, 2025
Oruka Therapeutics reports Q3 2025 results, beating EPS estimates. With a strong $500.9M cash position, the biotech advances its clinical pipeline for ORKA-001 and ORKA-002. 
Via Chartmill
News headline image
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Insider Report: The Bulls Can Thank Tech ↗
November 02, 2025
 
Via Benzinga
News headline image
Oruka Therapeutics to Present at Multiple November Investor Conferences
October 29, 2025
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗
October 06, 2025
U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Stocks
News headline image
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗
October 05, 2025
US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap